Skip to content
Back to search

NCT07527468Not yet recruiting

HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery

Summary

This study evaluates whether systematic intraoperative margin assessment using the Histolog® Scanner - a confocal fluorescence microscopy device - reduces the need for reoperation after breast-conserving surgery (lumpectomy) in women with lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), or invasive carcinoma with a DCIS component (NST+DCIS). After lumpectomy, the fresh specimen is imaged in real time by the surgeon using the Histolog® Scanner, which produces histological-quality images of the specimen surface without any tissue processing. This allows immediate assessment of surgical margins in the operating room, enabling the surgeon to perform additional tissue removal if needed before closing. Based on institutional data from 266 cases at CHVR (2021-2024), the current reoperation rate in this population is 11.3%. The study tests whether systematic use of the Histolog® Scanner in addition to standard care reduces this rate by 50% or more (to ≤5.6%). A total of 228 patients will be enrolled prospectively at the Centre Hospitalier du Valais Romand (CHVR), Sion, Switzerland. The reoperation decision is made by the multidisciplinary tumour board based on final histopathology results, independently of the intraoperative findings.

Eligibility criteria

1. Female patient, aged 18 years or older at time of surgery. 2. Pre-operative core needle biopsy (CNB) or vacuum-assisted biopsy (VAB) with histological diagnosis of one of the following: 1. invasive lobular carcinoma (ILC/CLI), 2. pure ductal carcinoma in situ (DCIS), or 3. invasive carcinoma of non-special type (NST) with an associated DCIS component. 3. Planned breast-conserving surgery (BCS / lumpectomy) at CHVR. 4. Signed electronic informed consent (eIC) obtained prior to any study procedure. Exclusion Criteria: 1. Pregnancy (confirmed or suspected) at time of surgery. 2. Prior neo-adjuvant treatment (hormonal therapy or chemotherapy) for the current breast cancer diagnosis. 3. Surgical indication for mastectomy rather than BCS. 4. Known hypersensitivity or allergy to acriflavine (fluorescent staining agent used with the Histolog Scanner). 5. Incapacity to provide informed consent. 6. Previous enrolment in this study.

Contacts

The trial team's contact details are shown on request.

See the official trial record
Status
Not yet recruiting
Phase
No phase (N/A)
Study type
Interventional
Countries
Switzerland
Sponsor
Hôpital du Valais(Other)
Protocol no.
HISMAR-CHVR-2025
Conditions
Breast Cancer, Ductal Carcinoma In Situ, Invasive Lobular Carcinoma, Breast Neoplasm Female
Interventions
Device

Treatments studied

  • Histolog® Scanner

Collaborators

SamanTree Medical SA

Locations · 1

  • Sion, SwitzerlandCentre Hospitalier du Valais Romand (CHVR)Not yet recruiting at this site

In total, worldwide, the only site listed in the registry is planned; recruitment has not opened yet.

Site status per the ClinicalTrials.gov registry (last update posted: April 14, 2026).

This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.

Other versions

These results are indicative and do not replace medical advice — discuss them with your doctor.